无能性
发表于 2025-3-23 12:38:50
http://reply.papertrans.cn/87/8615/861440/861440_11.png
大吃大喝
发表于 2025-3-23 15:07:42
Martin Berger,Walter Helmersdisease. Although new conventional drugs have been found to block the replication of this virus efficiently, new mutant strains continuously arise, which escape the inhibitory effect of such drugs. Furthermore, since HIV-1 integrates its genome into that of the host cell, dormant viruses persist in
散开
发表于 2025-3-23 19:26:05
http://reply.papertrans.cn/87/8615/861440/861440_13.png
exacerbate
发表于 2025-3-24 00:58:00
Martin Berger,Walter Helmerstment of many tumour types, and changing the paradigm of treatment in oncology by targeting immune cells rather than cancer cells. Antagonistic antibodies blocking immunosuppressive pathways such as PD-1/PD-L1 have shown anti-tumor activity in patients with advanced relapsed and refractory cancers t
现代
发表于 2025-3-24 04:28:34
http://reply.papertrans.cn/87/8615/861440/861440_15.png
让空气进入
发表于 2025-3-24 06:31:51
http://reply.papertrans.cn/87/8615/861440/861440_16.png
公式
发表于 2025-3-24 10:41:28
Martin Berger,Walter Helmers protein is highly immunogenic, which indicates that WT1 should be a promising target antigen for cancer immunotherapy. The identification of human WT1 cytotoxic T lymphocyte (CTL) epitopes and the demonstration using a mouse model that WT1 could serve in vivo as a target antigen for cancer immunoth
以烟熏消毒
发表于 2025-3-24 15:01:36
Martin Berger,Walter Helmers protein is highly immunogenic, which indicates that WT1 should be a promising target antigen for cancer immunotherapy. The identification of human WT1 cytotoxic T lymphocyte (CTL) epitopes and the demonstration using a mouse model that WT1 could serve in vivo as a target antigen for cancer immunoth
Irrepressible
发表于 2025-3-24 19:36:11
http://reply.papertrans.cn/87/8615/861440/861440_19.png
灯丝
发表于 2025-3-24 23:11:32
Martin Berger,Walter Helmers exert potent cytotoxicity against a variety of cancer cells irrespective of MHC class I expression, and bridge innate and adaptive immunity. They comprise 1–5 % of peripheral blood mononuclear cell (PBMC); the majority of them express the Vγ9Vδ2 T cell receptor that recognizes phosphoantigens. Ther